On Mar 26, we issued an updated research report on Myriad Genetics, Inc. MYGN. The stock carries a Zacks Rank #3 (Hold).
Shares of this Salt Lake City, UT-based molecular diagnostics provider have outperformed the broader industry over the past six months. The stock has rallied 19.2% compared with the industry’s 9.5% rise.
The company’s molecular-diagnostics portfolio has been gaining prominence in the MedTech space of late. We are particularly upbeat about its newly-launched product line. Myriad Genetics has been recording strong volumes of EndoPredict and GeneSight tests. In the Prolaris testing domain, volumes steadily expanded in double-digits during second-quarter fiscal 2019.
Myriad Genetics, Inc. Price
Myriad Genetics, Inc. Price | Myriad Genetics, Inc. Quote
Particularly, Myriad Genetics is focused on driving revenues by commercializing its innovative products including Vectra DA, Prolaris, myPath Melanoma, Myriad Genetics’s Companion Diagnostics, EndoPredict and myPlan Lung Cancer Test. Earlier, management expected each of the products to generate revenues of more than $50 million by fiscal 2020.
Moreover, Myriad Genetics has been consistently gaining reimbursement approvals. In the last reported quarter, the company announced the finalization of LCD (Local Coverage Determination) from Noridian for EndoPredict, thus extending the total coverage to around 90% of the U.S. market. Also, the Prolaris test is under evaluation by the revised NCCN (National Comprehensive Cancer Network) guidelines and has been covered by Medicare for the patients at intermediate risk.
Also, in order to gain reimbursement coverage on Vectra DA and GeneSight testing platforms, the company is constantly undertaking specific measures.
Meanwhile, Myriad Genetics faces stiff competition in the key BRACAnalysis market. The company expects the same to intensify due to the advancement of technology. We believe, tough headwinds might reduce the prices of expensive tests provided by the company. This might in turn, impede the stock’s margin improvement.
Moreover, as the company receives a considerable portion of its revenues as well as pays part of its expenses in foreign currencies, it is exposed to exchange rate fluctuations between foreign notes and the U.S. dollar.
Some better-ranked stocks in the broader medical space are Stryker Corporation SYK, Penumbra, Inc., PEN and Varian Medical Systems, Inc VAR. Notably, each currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker’s long-term earnings growth rate is expected to be 10%
Penumbra’s long-term earnings growth rate is anticipated at 20.9%.
Varian’s long-term earnings growth rate is predicted to be 8%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
Penumbra, Inc. (PEN): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis Report
Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.